631 results on '"Cutillas, Pedro R."'
Search Results
2. Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes
3. Microtubule-associated proteins MAP7 and MAP7D1 promote DNA double-strand break repair in the G1 cell cycle phase
4. Causal Role for Neutrophil Elastase in Thoracic Aortic Dissection in Mice
5. Maternal Immune Activation imprints translational dysregulation and differential MAP2 phosphorylation in descendant neural stem cells
6. Supplementary Figure 7 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
7. Supplementary Figure 5 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
8. TABLE 2 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
9. Supplementary Figure 8 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
10. Data from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
11. FIGURE 3 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
12. Supplementary Figure 1 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
13. FIGURE 7 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
14. FIGURE 6 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
15. Supplementary Figure 6 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
16. Supplementary Figure 2 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
17. Supplementary Figure 3 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
18. FIGURE 1 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
19. FIGURE 4 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
20. FIGURE 5 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
21. Supplementary Figure 4 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
22. TABLE 1 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
23. FIGURE 2 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate
24. Implementation of Clinical Phosphoproteomics and Proteomics for Personalized Medicine
25. Comparison of multiple modalities for drug response prediction with learning curves using neural networks and XGBoost
26. Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans
27. Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs
28. Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes
29. A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity
30. Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring
31. S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
32. Characterization of four subtypes in morphologically normal tissue excised proximal and distal to breast cancer
33. Community detection in empirical kinase networks identifies new potential members of signalling pathways
34. In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients
35. Cancer associated fibroblast FAK regulates malignant cell metabolism
36. Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells
37. Abstract 5841: Exploring the role of versican in immune exclusion within triple negative breast cancer
38. Supplementary Tables 10 - 14 from Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers
39. Figure S2 from TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer
40. Supplementary Tables 4 - 9 from Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers
41. Table S3 from TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer
42. Data from Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers
43. Data from TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer
44. Supplementary Tables 1 - 3 from Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers
45. Supplementary Tables 15 - 25 from Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers
46. Figures S1 - S6 from Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers
47. Table S1 S2 S3 legend from TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer
48. Data from Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets
49. Supplementary Figures and Tables from Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets
50. Supplementary Table S3 from A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.